List view / Grid view
Researchers have identified a structural loop in the SARS-CoV-2 S protein and a sequence of four amino acids that they say could help explain its high transmission rate.
Tests have shown that LAL assays produced from L. polyphemus in aquaculture often has a higher activity than lyophilised and preserved LAL from commercial kits.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
